[A case of long survival with unresectable duodenal papilla cancer treated with oral chemotherapy using combination UFT and cyclophosphamide].

Abstract

A 69-year-old female patient underwent a choledochojejunostomy for unresectable duodenal papilla cancer with para-aortic lymph node metastases. Both tegafur-uracil(UFT) and cyclophosphamide were given orally every day after surgery. Twenty-eight months from the initiation of the chemotherapy the tumor had remarkably reduced and the objective response was evaluated as a PR. The patient is now doing well. Lymph node metastasis is considered an important prognostic factor of papilla Vater carcinoma, and especially with para-aortic lymph node metastases the long-term prognosis is poor. Combination chemotherapy using UFT and cyclophosphamide would be a therapeutic option for elderly or high-risk patients.

• Authors: Ryuichi Mikami, Kazuyoshi Nishihara, Hiroaki Matsunaga, Yuji Abe, Shoshu Mitsuyama, Toshifumi Nasu, Ichiro Yamamoto, Satoshi Toyoshima, Makoto Motooka
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 35 Issue 8 Pg. 1399-401 (Aug 2008) ISSN: 0385-0684 [Print] Japan
• PMID: 18701858 (Publication Type: Case Reports, Journal Article)

Chemical References

• Biomarkers, Tumor
• Tegafur
• Uracil
• Cyclophosphamide

Topics

• Adenoma (drug therapy, pathology)
• Administration, Oral
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Biomarkers, Tumor (blood)
• Cyclophosphamide (administration & dosage, therapeutic use)
• Duodenal Neoplasms (blood, diagnostic imaging, drug therapy, pathology)
• Duodenoscopy
• Female
• Humans
• Tegafur (administration & dosage, therapeutic use)
• Time Factors
• Tomography, X-Ray Computed
• Uracil (administration & dosage, therapeutic use)